| Literature DB >> 28550042 |
Trisha A Dant1, Kaifeng L Lin2, Danny W Bruce2, Stephanie A Montgomery2,3, Oleg V Kolupaev2, Hemamalini Bommiasamy2, Lisa M Bixby2, John T Woosley3, Karen P McKinnon1,2, Frank J Gonzalez4, Bruce R Blazar5, Benjamin G Vincent2,6,7, James M Coghill2,6, Jonathan S Serody1,2,6.
Abstract
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that affects the function and development of immune cells. Here, we show that recipient mice receiving AhR-/- T cells have improved survival and decreased acute graft-versus-host disease (aGVHD) in 2 different murine allogeneic bone marrow transplant (BMT) models. We also show that CD4+ T cells lacking AhR demonstrate reduced accumulation in secondary lymphoid tissue because of low levels of proliferation 4 days after BMT. Additionally, we found a significant increase in the quantity of peripherally induced regulatory donor T (pTreg) cells in the colon of recipients transplanted with AhR-/- T cells 14 days after transplant. Blockade of AhR using a clinically available AhR antagonist greatly enhanced the in vitro generation of inducible Treg (iTreg) cells from naïve CD4+ human T cells. We have identified AhR as a novel target on donor T cells that is critical to the pathogenesis of aGVHD.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28550042 PMCID: PMC5520467 DOI: 10.1182/blood-2016-08-734244
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113